1150 Seventeenth Street, NW, Washington, DC 20036
(Two blocks from Farragut North Metro)
The pervasive distrust of the pharmaceutical industry among academics, regulators and medical practitioners could adversely affect patients' health. At an AEI event on Thursday evening, a panel of health experts discussed their research on the unintended consequences of anti-industry bias.
George Chressanthis of Temple University began with an explanation of his recently published paper on the effect of restricting pharmaceutical representatives' access to doctors. His research demonstrates that physicians with limited access to representatives react slower to new medical information, taking longer to begin prescribing breakthrough drugs and to stop prescribing medications with recently discovered dangerous side effects.
ZS Associates' Nitin Jain (a co-author of Chressanthis's paper) elaborated that their results were significant even after controlling for other factors such as practice size or managed care that might affect access to pharmaceutical representatives. Tom Stossel of Harvard University Medical School then discussed his findings detailing prejudice towards the pharmaceutical industry. In a paper published in April, Stossel found that high-tier medical journals overemphasize the risk of collaboration between industry, practice and academia without mentioning the benefits that can arise from this collaboration. The bias Stossel describes is at the root of the movement to restrict representatives' access to prescribers, a movement which — as Chressanthis and Jain explained — may harm the patients it aims to protect.
-- Catherine Griffin
Nearly every week brings both good and bad news about the safety and effectiveness of pharmaceutical products. A timely and clinically relevant way to disseminate this news to physicians and other prescribers is via field and sales communications by pharmaceutical and biotechnology companies. But a growing anti-industry bias — held by academic researchers, health insurers, regulators and others who seek to constrain spending on new medicines — is determined to restrict access to prescribers.
This session will present important new findings on the dangers of blocking pharmaceutical company communications to prescribers. Among the negative effects are continued use of medications despite new safety warnings and slower uptake of breakthrough, potentially life-saving new medicines.
The event will be followed by a wine and cheese reception honoring the late Jack Calfee of AEI, who was excited about this research before his untimely passing.
Full video will be posted within 24 hours.
George Chressanthis, Temple University’s Fox School of Business
Nitin Jain, ZS Associates
Thomas P. Stossel, M.D., Brigham and Women’s Hospital and Harvard University Medical School
J.D. Kleinke, AEI
Wine and Cheese Reception
For more information, please contact Catherine Griffin at email@example.com, 202.862.5920.
For media inquiries, please contact Véronique Rodman at firstname.lastname@example.org, 202.862.4871.
George Chressanthis has, since July 2010, been a professor of health care management and marketing and acting director for the Center of Healthcare Research and Management at the Fox School of Business and Management at Temple University. Before working at Temple, he was senior director for commercial strategic analysis at AstraZeneca Pharmaceuticals, working at their U.S. headquarters. His pharmaceutical expertise covers numerous functional areas across commercial operations. Other industry positions include work at Wyeth-Ayerst Laboratories, IMS Health and ZS Associates for a total industry career spanning over 14 years. He researches and presents on numerous critical pharmaceutical topics at major academic and industry conferences. Before entering the pharmaceutical industry, Chressanthis was a tenured professor of economics and associate professor of political science at Mississippi State University and held other faculty positions at Texas Tech University and Saginaw Valley State College.
Nitin Jain is a principal at ZS Associates’ world headquarters in Evanston, Illinois. ZS Associates is a global sales and marketing consulting firm specializing in the pharmaceutical industry. Jain works with many large- to medium-sized pharmaceutical companies on topics ranging from sales force design, managed care strategy, marketing-mix planning and advanced patient-level data analytics. He is also the managing principal of ZS Associates’ Managed Care practice area. Jain joined ZS Associates in 2001.
J. D. Kleinke is an expert on health care business strategy and entrepreneurship and was instrumental in the creation of four health care information organizations. He has also advised established and start-up companies on health care business, product and technology strategy. Kleinke writes on the business of health care, health insurance and benefits as well as about doctors and the culture of medicine. His books include “Bleeding Edge: The Business of Health Care in the New Century” (Jones & Bartlett Learning, 1998), “Oxymorons: The Myth of a U.S. Health Care System” (Jossey-Bass, 2001) and “Catching Babies” (Fourth Chapter Books, 2011). At AEI, he is studying the interplay between health policy, health care market dynamics and health venture formation; the influence of information technology and medical technology on the overall health economy; and the impact of medical culture on health care organizations, markets and public health.
Thomas P. Stossel, M.D., was head of the Hematology and Oncology Division of the Department of Medicine at Massachusetts General Hospital from 1976 until 1991, co-director of the Hematology Division at Brigham & Women’s Hospital through 2006 and is currently director of the Division of Translational Medicine at Brigham & Women’s and the American Cancer Society Professor of Medicine at Harvard Medical School. For his research on cell motility, he has received the Dameshek and Thomas Awards of the American Society of Hematology, been elected a member of the American Society for Clinical Investigation, the Association of American Physicians, the National Academy of Sciences, the American Academy of Arts and Sciences and the Institute of Medicine. He was president of the American Society for Clinical Investigation and editor-in-chief of its Journal of Clinical Investigation. He also served as president of the American Society of Hematology and is currently editor-in-chief of Current Opinion in Hematology. He is a director of Velico Corporation and the scientific founder of BioAegis Therapeutics. Stossel was a trustee of the American Council on Science and Health and a co-founder of The Association of Clinical Researchers and Educators. Stossel and his wife have established a nonprofit, Options for Children, which provides dental prevention and treatment to orphans in Zambia.